Connect your AI

Denali Therapeutics Inc. DNLI Shares (Basic)

Shares (Basic) at other companies

Eli LillyLLY

894.5M-0.5%

Regeneron PharmaceuticalsREGN

104M-2.5%

Ultragenyx PharmaceuticalRARE

100.6M+4.5%

Viking TherapeuticsVKTX

115.6M+3.1%

uniQureQURE

62.7M+18.1%

BiogenBIIB

147.2M+0.8%

Other financials

Income statement

Revenue-—

Operating income-$137.4M+5.6%

Net income-$128.4M+3.4%

EPS (diluted)-$0.69+11.5%

Balance sheet

Cash & equivalents$390.7M+551%

Total debt$40.0M-22.3%

Total equity$926.1M-17.5%

Total assets$1.3B-0.4%

Cash flow

Operating cash flow-$131.2M+0.2%

CapEx$2.5M-51.4%

Free cash flow-$133.7M+2.1%

Valuation

Market cap$3.93B+54.2%

Profitability

Operating margin-37,938%-37,986pp

Net margin-33,121.9%-33,159pp

FCF margin-31,736.3%-31,830pp

Returns & leverage

Return on equity-49.6%+34.2pp

Debt / equity0×0.0×

Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfSharesOutstandingBasic.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s shares (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Denali Therapeutics Inc.'s shares (basic)?: Denali Therapeutics Inc. (DNLI) reported shares (basic) of 186.6M in Q1 2026.
How has Denali Therapeutics Inc.'s shares (basic) changed year-over-year?: Denali Therapeutics Inc.'s shares (basic) increased by 9.0% year-over-year, from 171.2M to 186.6M.
What is the long-term trend for Denali Therapeutics Inc.'s shares (basic)?: Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s shares (basic) has grown at a 9.1% compound annual growth rate (CAGR), from 485.4M to 687.7M.
What does shares (basic) mean?: The time-weighted average number of common shares outstanding during the period, used as the denominator for basic EPS calculations.